Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Stem cell"" wg kryterium: Temat


Tytuł :
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Autorzy :
Kaddu-Mulindwa D; Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, Germany. Electronic address: .
Gödel P; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne Essen Lymphoma Working Group.
Kutsch N; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne Essen Lymphoma Working Group.
Heger JM; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne Essen Lymphoma Working Group.
Scheid C; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne Essen Lymphoma Working Group.
Borchmann P; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne Essen Lymphoma Working Group.
Holtick U; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne Essen Lymphoma Working Group.
Held G; Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, Germany.
Thurner L; Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, Germany.
Bewarder M; Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, Germany.
Rixecker T; Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, Germany.
Bittenbring JT; Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, Germany; Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, Germany.
Pokaż więcej
Źródło :
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Jul; Vol. 22 (7), pp. e498-e506. Date of Electronic Publication: 2022 Jan 13.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/methods
Lymphoma*/drug therapy
Lymphoma, B-Cell*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Consolidation Chemotherapy ; Humans ; Melphalan/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Retrospective Studies ; Salvage Therapy/methods ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Outcomes of stem cell mobilization and engraftment in patients with multiple myeloma according to CD56 expression status.
Autorzy :
Iltar U; Akdeniz University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya, Turkey. Electronic address: utq_.
Ataş Ü; Akdeniz University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya, Turkey.
Vural E; Akdeniz University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya, Turkey.
Alhan FN; Akdeniz University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya, Turkey.
Yücel OK; Akdeniz University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya, Turkey.
Salim O; Akdeniz University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya, Turkey.
Undar L; Akdeniz University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya, Turkey.
Pokaż więcej
Źródło :
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2022 Jun; Vol. 61 (3), pp. 103351. Date of Electronic Publication: 2022 Jan 07.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/methods
Multiple Myeloma*/therapy
Antigens, CD34/metabolism ; Hematopoietic Stem Cell Mobilization/methods ; Humans ; Transplantation, Autologous/methods
Czasopismo naukowe
Tytuł :
Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
Autorzy :
Alsaeed AS; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Najib MJ; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Al Amoudi SM; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Elhemaidi IY; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Absi AA; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Al Ahmadi MD; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Eldadah SK; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Rajkhan WA; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Khalil MM; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Almohammadi MH; From the Oncology Department (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil), Princess Noorah Oncology Center; from the Department of Pathology and Laboratory Medicine (Najib, Almohammadi), King Abdulaziz Medical City, Ministry of the National Guard Health Affairs; from the Research Unit (Alsaeed, Najib, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Eldadah, Rajkhan, Khalil, Almohammadi), King Abdullah International Medical Research Center; from the Department of Medicine (Alsaeed, Al Amoudi, Elhemaidi, Absi, Al Ahmadi, Almohammadi), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, and from the Saudi Society for Blood and Marrow Transplantation (Alsaeed), Riyadh Kingdom of Saudi Arabia.
Pokaż więcej
Źródło :
Saudi medical journal [Saudi Med J] 2022 Jun; Vol. 43 (6), pp. 626-632.
Typ publikacji :
Journal Article
MeSH Terms :
Cyclams*
Hematopoietic Stem Cell Transplantation*
Heterocyclic Compounds*
Lymphoma*/therapy
Multiple Myeloma*/therapy
Peripheral Blood Stem Cells*/metabolism
Adult ; Antigens, CD34/metabolism ; Benzylamines ; Hematopoietic Stem Cell Mobilization ; Humans ; Retrospective Studies ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Autorzy :
Chong CY; City of Hope National Medical Center.
Pokaż więcej
Źródło :
Clinical journal of oncology nursing [Clin J Oncol Nurs] 2022 Jun 01; Vol. 26 (3), pp. 252-256.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/drug therapy
Humans ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
In vivo study to assess dosage of allogeneic pig retinal progenitor cells: Long-term survival, engraftment, differentiation and safety.
Autorzy :
Abud MB; Federal University of Goias, Goiania, GO, Brazil.; Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Baranov P; Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Patel S; ReNeuron, Pencoed, UK.
Hicks CA; ReNeuron, Pencoed, UK.
Isaac DLC; Federal University of Goias, Goiania, GO, Brazil.
Louzada RN; Federal University of Goias, Goiania, GO, Brazil.; Postgraduate Program in Surgical Science, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Dromel P; Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Singh D; Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Sinden J; ReNeuron, Pencoed, UK.
Ávila MP; Federal University of Goias, Goiania, GO, Brazil.
Young M; Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Pokaż więcej
Źródło :
Journal of cellular and molecular medicine [J Cell Mol Med] 2022 Jun; Vol. 26 (11), pp. 3254-3268. Date of Electronic Publication: 2022 Apr 28.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Retina*/metabolism
Animals ; Cell Differentiation/physiology ; Green Fluorescent Proteins/genetics ; Green Fluorescent Proteins/metabolism ; Stem Cell Transplantation ; Swine ; Swine, Miniature
Czasopismo naukowe
Tytuł :
Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Autorzy :
Chu TH; BioMedical Sciences Graduate Program, Chonnam National University, Gwangju, Republic of Korea.; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, 322 Seoyangro, Hwasun, Jeollanamdo, Seoul, 58128, Republic of Korea.
Jung SH; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, 322 Seoyangro, Hwasun, Jeollanamdo, Seoul, 58128, Republic of Korea.
Kim K; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Lee JH; Gachon University Gil Medical Center, Incheon, Republic of Korea.
Mun YC; Ewha Womans University School of Medicine, Seoul, Republic of Korea.
Bang SM; Seoul National University Bundang Hospital, Seoul, Republic of Korea.
Yoon DH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee HS; Kosin University Gospel Hospital, Busan, Republic of Korea.
Min CK; Department of Hematology, College of Medicine, Seoul St. Mary's Hematology Hospital, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 137-070, Republic of Korea. .
Lee JJ; BioMedical Sciences Graduate Program, Chonnam National University, Gwangju, Republic of Korea. .; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, 322 Seoyangro, Hwasun, Jeollanamdo, Seoul, 58128, Republic of Korea. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2022 Jun; Vol. 101 (6), pp. 1217-1226. Date of Electronic Publication: 2022 Apr 21.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*
Plasmacytoma*/therapy
Humans ; Neoplasm Recurrence, Local/therapy ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors.
Autorzy :
Tsumanuma R; Department of Hematology, Yamagata Prefectural Central Hospital, 1800 Aoyagi, Yamagata-City, Yamagata, 990-2292, Japan. .
Omoto E; Department of Hematology, Yamagata Prefectural Central Hospital, 1800 Aoyagi, Yamagata-City, Yamagata, 990-2292, Japan.
Kumagai H; Department of Hematology, Yamagata Prefectural Central Hospital, 1800 Aoyagi, Yamagata-City, Yamagata, 990-2292, Japan.
Katayama Y; Department of Hematology, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Iwato K; Department of Hematology, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Aoki G; Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan.
Sato Y; Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan.
Tsutsumi Y; Department of Hematology, Hakodate City Hospital, Hakodate, Japan.
Tsukada N; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Iino M; Department of Hematology and Chemotherapy, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Kodera Y; Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan.
Okamoto S; Division of Hematology, Department of Medicine, Keio University School of Medicine, Minato, Japan.
Yabe H; Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2022 Jun; Vol. 115 (6), pp. 882-889. Date of Electronic Publication: 2022 Apr 09.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Biosimilar Pharmaceuticals*/adverse effects
Hematopoietic Stem Cell Transplantation*/adverse effects
Adolescent ; Adult ; Aged ; Antigens, CD34 ; Female ; Filgrastim/adverse effects ; Granulocyte Colony-Stimulating Factor/adverse effects ; Hematopoietic Stem Cell Mobilization ; Humans ; Male ; Middle Aged ; Prospective Studies ; Recombinant Proteins ; Tissue Donors ; Young Adult
Czasopismo naukowe
Tytuł :
Efficacy and safety of a reduced dose of plerixafor in combination with granulocyte colony-stimulating factor in healthy haploidentical stem cell donors.
Autorzy :
Kurnikova E; Transfusion Medicine Service, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Trakhtman P; Transfusion Medicine Service, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Balashov D; Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Garloeva J; Transfusion Medicine Service, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Kumukova I; Transfusion Medicine Service, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Khismatullina R; Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Pershin D; Transplantation Immunology and Immunotherapy Laboratory, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Shelikhova L; Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Novichkova G; Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Maschan A; Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Pokaż więcej
Źródło :
Vox sanguinis [Vox Sang] 2022 Jun; Vol. 117 (6), pp. 853-861. Date of Electronic Publication: 2022 Mar 24.
Typ publikacji :
Journal Article
MeSH Terms :
Cyclams*
Hematopoietic Stem Cell Transplantation*/methods
Heterocyclic Compounds*/pharmacology
Adult ; Antigens, CD34/metabolism ; Benzylamines ; Body Weight ; Granulocyte Colony-Stimulating Factor/pharmacology ; Hematopoietic Stem Cell Mobilization/methods ; Humans ; Prospective Studies ; Stem Cells/metabolism
Czasopismo naukowe
Tytuł :
Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis.
Autorzy :
Spierings J; Division of Medicine, Department of Inflammation, Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, University College London, London, UK.; Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Nihtyanova SI; Division of Medicine, Department of Inflammation, Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, University College London, London, UK.
Derrett-Smith E; Division of Medicine, Department of Inflammation, Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, University College London, London, UK.
Clark KEN; Division of Medicine, Department of Inflammation, Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, University College London, London, UK.
van Laar JM; Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Ong V; Division of Medicine, Department of Inflammation, Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, University College London, London, UK.
Denton CP; Division of Medicine, Department of Inflammation, Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, University College London, London, UK.
Pokaż więcej
Źródło :
Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2022 May 05; Vol. 61 (5), pp. 1948-1956.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Hypertension, Pulmonary*/etiology
Scleroderma, Diffuse*/drug therapy
Scleroderma, Systemic*/drug therapy
Aged ; Dihydrotachysterol/therapeutic use ; Humans ; Male ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Splenic rupture following lenograstim in post-autologous stem cell transplantation treated with emergency open splenectomy: a case report and literature review.
Autorzy :
Markovic U; Oncohematology and BMT Unit, Mediterranean Institute of Oncology, Viagrande, Italy.; Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
Colarossi C; Surgery Unit, Gretter Clinic, Catania, Italy.
Iuppa A; Pathology Unit, Department of Experimental Oncology, Mediterranean Institute of Oncology, Viagrande, Italy.; Surgery Unit, Department of Experimental Oncology, Mediterranean Institute of Oncology, Viagrande, Italy.
Scire P; Oncohematology and BMT Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
Gorgone A; Oncohematology and BMT Unit, Mediterranean Institute of Oncology, Viagrande, Italy.; Department of Hematology, ARNAS Garibaldi, Catania, Italy.
Galbo F; Oncohematology and BMT Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
Amato G; Oncohematology and BMT Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
Moschetti G; Oncohematology and BMT Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
Pokaż więcej
Źródło :
The Journal of international medical research [J Int Med Res] 2022 May; Vol. 50 (5), pp. 3000605221095504.
Typ publikacji :
Case Reports; Journal Article; Review
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Splenic Rupture*/etiology
Splenic Rupture*/surgery
Granulocyte Colony-Stimulating Factor/adverse effects ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Hematopoietic Stem Cell Mobilization/adverse effects ; Humans ; Lenograstim ; Splenectomy ; Transplantation, Autologous/adverse effects
Czasopismo naukowe
Tytuł :
Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol.
Autorzy :
Puyade M; Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.; Centre d'Investigation Clinique (CIC)-1402, CHU de Poitiers, Poitiers, France.
Brunet F; Division of Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada.
Carolina R; Division of Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada.; Department of Medicine, University of Ottawa, Ontario.
Fergusson N; Ottawa Hospital Research Institute, Ottawa, Ontario.
Makedonov I; Department of Medicine, University of Ottawa, Ontario.
Freedman MS; Division of Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada.; Department of Medicine, University of Ottawa, Ontario.; Ottawa Hospital Research Institute, Ottawa, Ontario.
Atkins H; Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.; Department of Medicine, University of Ottawa, Ontario.; Ottawa Hospital Research Institute, Ottawa, Ontario.
Pokaż więcej
Źródło :
Current protocols [Curr Protoc] 2022 May; Vol. 2 (5), pp. e437.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/methods
Multiple Sclerosis*/therapy
Cyclophosphamide/therapeutic use ; Hematopoietic Stem Cell Mobilization ; Humans ; Transplantation, Autologous/methods
Czasopismo naukowe
Tytuł :
Impact of Human T Cell Lymphotropic Virus Type 1 and 2 Infection on Survival Following Stem Cell Transplantation.
Autorzy :
Gupta VK; Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
El-Jawahri A; Division of Hematology and Oncology, Harvard Medical School, Boston, Massachusetts.
Orkev G; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Johnson MH; Center for International Blood and Marrow Transplant Research Statistical Center, Milwaukee Campus, Milwaukee, Wisconsin.
Weinberg J; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
Goodrich C; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
Janakiram M; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Sloan JM; Division of Hematology and Oncology, Boston University School of Medicine, Boston, Massachusetts. Electronic address: .
Pokaż więcej
Źródło :
Transplantation and cellular therapy [Transplant Cell Ther] 2022 May; Vol. 28 (5), pp. 276.e1-276.e5. Date of Electronic Publication: 2022 Feb 02.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Human T-lymphotropic virus 1*
Leukemia-Lymphoma, Adult T-Cell*/therapy
Adult ; Humans ; Stem Cell Transplantation ; T-Lymphocytes
Czasopismo naukowe
Tytuł :
Clinical implication of residual MIBG-positive disease in the follow-up of high-risk neuroblastoma treated with tandem high-dose chemotherapy and autologous stem cell transplantation.
Autorzy :
Seo ES; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Shin M; Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Lim H; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Cho HW; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Ju HY; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Cho YS; Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Yoo KH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Koo HH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Lee JW; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Sung KW; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2022 Jul; Vol. 69 (7), pp. e29502. Date of Electronic Publication: 2021 Dec 10.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Neuroblastoma*/drug therapy
Neuroblastoma*/therapy
3-Iodobenzylguanidine ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Follow-Up Studies ; Humans ; Infant ; Neoplasm, Residual/drug therapy ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios.
Autorzy :
Qiu KY; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.
Liao XY; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.
Liu Y; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.; Hematologic Laboratory of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.
Huang K; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.
Li Y; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China.
Fang JP; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China. .; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China. .
Zhou DH; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China. .; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, PR China. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2022 Jun 27; Vol. 13 (1), pp. 3679. Date of Electronic Publication: 2022 Jun 27.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Child ; Genetic Testing ; Humans ; Mutation ; Stem Cell Transplantation ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
Is stem cell transplantation safe and effective in multiple sclerosis?
Autorzy :
Sharrack B; Department of Neurology and Sheffield NIHR Neuroscience BRC, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, UK .; Clinical Trials Research Unit, University of Sheffield, Sheffield, UK .; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK .; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK .; Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK .
Petrie J; Department of Neurology and Sheffield NIHR Neuroscience BRC, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, UK.; Clinical Trials Research Unit, University of Sheffield, Sheffield, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.; Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK.
Coles A; Department of Neurology and Sheffield NIHR Neuroscience BRC, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, UK.; Clinical Trials Research Unit, University of Sheffield, Sheffield, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.; Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK.
Snowden JA; Department of Neurology and Sheffield NIHR Neuroscience BRC, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, UK.; Clinical Trials Research Unit, University of Sheffield, Sheffield, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.; Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK.
Pokaż więcej
Źródło :
BMJ (Clinical research ed.) [BMJ] 2022 Jun 09; Vol. 377, pp. e061514. Date of Electronic Publication: 2022 Jun 09.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Multiple Sclerosis*/surgery
Humans ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option.
Autorzy :
Lazana I; Department of Haematological Medicine, King's College Hospital, London, UK.
Floro L; Department of Haematological Medicine, King's College Hospital, London, UK.
Christmas T; Department of Haematological Medicine, King's College Hospital, London, UK.
Shah S; Renal Unit, King's College Hospital, London, UK.
Bramham K; Renal Unit, King's College Hospital, London, UK.
Cuthill K; Department of Haematological Medicine, King's College Hospital, London, UK.
Bassett P; Statsconsultancy Ltd, London, UK.
Schey S; Department of Haematological Medicine, King's College Hospital, London, UK.; Department of Haematology, Guy's and St Thomas' Hospital, London, UK.
Kazmi M; Department of Haematological Medicine, King's College Hospital, London, UK.; Department of Haematology, Guy's and St Thomas' Hospital, London, UK.
Potter V; Department of Haematological Medicine, King's College Hospital, London, UK.
Pagliuca A; Department of Haematological Medicine, King's College Hospital, London, UK.
Streetly M; Department of Haematological Medicine, King's College Hospital, London, UK.; Department of Haematology, Guy's and St Thomas' Hospital, London, UK.
Benjamin R; Department of Haematological Medicine, King's College Hospital, London, UK. .; Department of Haematology, Guy's and St Thomas' Hospital, London, UK. .
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2022 Jun; Vol. 57 (6), pp. 959-965. Date of Electronic Publication: 2022 Apr 12.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/methods
Multiple Myeloma*/complications
Multiple Myeloma*/therapy
Renal Insufficiency, Chronic*/complications
Renal Insufficiency, Chronic*/therapy
Humans ; Retrospective Studies ; Stem Cell Transplantation/adverse effects ; Transplantation, Autologous/methods ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant.
Autorzy :
Shipton MJ; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Kinsella PM; Department of Microbiology, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Davis T; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Azzato F; Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Taiaroa G; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Szer J; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Routledge D; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Smibert O; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. .; Department of Infectious Diseases, Austin Health, Melbourne, VIC, Australia. .
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2022 Jun; Vol. 57 (6), pp. 1028-1030. Date of Electronic Publication: 2022 Apr 11.
Typ publikacji :
Letter
MeSH Terms :
Brain Diseases*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Neurotoxicity Syndromes*
Humans ; Stem Cell Transplantation/adverse effects
Opinia redakcyjna
Tytuł :
A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.
Autorzy :
Liu H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Liu W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Li R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Jiao Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Huang W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Yi S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Lv R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Deng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
An G; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Wang T; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Sui W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Fu M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Zhao Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China.
Zou D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China. .
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2022 Jun; Vol. 57 (6), pp. 1017-1020. Date of Electronic Publication: 2022 Apr 07.
Typ publikacji :
Letter
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Lymphoma*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Deoxycytidine/analogs & derivatives ; Etoposide/therapeutic use ; Humans ; Stem Cell Transplantation ; Transplantation Conditioning ; Transplantation, Autologous
Opinia redakcyjna
Tytuł :
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group.
Autorzy :
Buhtoiarov IN; Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic Children's, Cleveland, Ohio, USA.
Mba NI; Department of Pediatric Hematology and Oncology, Driscoll Children's Hospital, Corpus Christi, Texas, USA.
Santos CDL; Department of Pediatric Hematology and Oncology, Driscoll Children's Hospital, Corpus Christi, Texas, USA.
McCarten KM; Imaging and Radiation Oncology Core Rhode Island, Lincoln, Rhode Island, USA.
Metzger ML; Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pei Q; Children's Oncology Group, Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
Bush R; Cytel, Inc., Waltham, Massachusetts, USA.
Baker K; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Kelly KM; Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Cole PD; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2022 Jun; Vol. 69 (6), pp. e29649. Date of Electronic Publication: 2022 Mar 26.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease*/drug therapy
Hodgkin Disease*/pathology
Immunoconjugates*/therapeutic use
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Brentuximab Vedotin ; Child ; Deoxycytidine/analogs & derivatives ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Salvage Therapy ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma.
Autorzy :
Rees MJ; Department of Clinical Haematology, Austin Health, Melbourne, VIC, Australia. .
Panigrahi A; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Harrison SJ; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
Spencer A; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia.
Khong T; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia.
Gibbs S; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia.; Department of Haematology, Eastern Health, Melbourne, VIC, Australia.
Hocking J; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia.; Department of Haematology, Eastern Health, Melbourne, VIC, Australia.
Grigg A; Department of Clinical Haematology, Austin Health, Melbourne, VIC, Australia.
Zantomio D; Department of Clinical Haematology, Austin Health, Melbourne, VIC, Australia.
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2022 Jun; Vol. 57 (6), pp. 1001-1003. Date of Electronic Publication: 2022 Mar 28.
Typ publikacji :
Letter
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/drug therapy
Antigens, CD34 ; Autografts ; Cyclophosphamide/pharmacology ; Cyclophosphamide/therapeutic use ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Hematopoietic Stem Cell Mobilization ; Humans
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies